晶苑國際(02232.HK)獲納入恒生綜合指數成份股
格隆匯3月10日丨晶苑國際(02232.HK)發佈公吿,公司已獲恒生指數有限公司選定並將納入恒生綜合指數成份股,自2025年3月10日起生效。恒生綜合指數是一項全面的香港市場指標,涵蓋了在香港聯交所主板上市的公司總市值最高的95%,可以用作指數基金、互惠基金及業績表現的基準。獲納入恒生綜合指數將令公司股份符合資格於滬港通及深港通(中國香港與中國內地投資者進行股份交易的渠道)進行買賣。
董事會認為,公司獲納入恒生綜合指數反映資本市場對公司業務表現及價值的高度認可,將有助擴大公司股東基礎並增加其股份交易的流通性,從而提高公司於資本市場的投資價值及聲譽。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.